JP2009505640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009505640A5 JP2009505640A5 JP2008525635A JP2008525635A JP2009505640A5 JP 2009505640 A5 JP2009505640 A5 JP 2009505640A5 JP 2008525635 A JP2008525635 A JP 2008525635A JP 2008525635 A JP2008525635 A JP 2008525635A JP 2009505640 A5 JP2009505640 A5 JP 2009505640A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- antibody
- disease
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 14
- 239000003446 ligand Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 4
- 102000053602 DNA Human genes 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 230000009257 reactivity Effects 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108020004682 Single-Stranded DNA Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001982 diacylglycerols Chemical class 0.000 claims 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 2
- 201000008980 hyperinsulinism Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010051161 Hyperglucagonaemia Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 206010043706 Thyroid cyst Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000001943 adrenal medulla Anatomy 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000035880 hyperglucagonemia Effects 0.000 claims 1
- 230000003832 immune regulation Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- -1 phospholipid glycan Chemical class 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 210000003079 salivary gland Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000003699 striated muscle Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0516527A GB0516527D0 (en) | 2005-08-11 | 2005-08-11 | Peptides |
| GB0609920A GB0609920D0 (en) | 2006-05-18 | 2006-05-18 | Peptides |
| GB0609921A GB0609921D0 (en) | 2006-05-18 | 2006-05-18 | Peptides |
| PCT/GB2006/002977 WO2007017686A2 (en) | 2005-08-11 | 2006-08-09 | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013024857A Division JP5738333B2 (ja) | 2005-08-11 | 2013-02-12 | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009505640A JP2009505640A (ja) | 2009-02-12 |
| JP2009505640A5 true JP2009505640A5 (https=) | 2009-09-24 |
Family
ID=37056087
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525635A Pending JP2009505640A (ja) | 2005-08-11 | 2006-08-09 | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド |
| JP2013024857A Expired - Fee Related JP5738333B2 (ja) | 2005-08-11 | 2013-02-12 | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013024857A Expired - Fee Related JP5738333B2 (ja) | 2005-08-11 | 2013-02-12 | 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9243062B2 (https=) |
| EP (3) | EP1919952B1 (https=) |
| JP (2) | JP2009505640A (https=) |
| KR (2) | KR101527334B1 (https=) |
| CN (1) | CN105017423B (https=) |
| AU (1) | AU2006277785B2 (https=) |
| BR (1) | BRPI0614366A2 (https=) |
| CA (1) | CA2618796C (https=) |
| CU (1) | CU23793B7 (https=) |
| CY (1) | CY1120640T1 (https=) |
| DK (1) | DK2594591T3 (https=) |
| EA (1) | EA015629B1 (https=) |
| ES (1) | ES2679994T3 (https=) |
| GB (1) | GB2429013C (https=) |
| IL (3) | IL189407A (https=) |
| NZ (3) | NZ566245A (https=) |
| WO (1) | WO2007017686A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| EP2154969B1 (en) * | 2007-05-16 | 2015-11-18 | The Brigham and Women's Hospital, Inc. | Treatment of synucleinopathies |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| NZ581835A (en) * | 2007-06-12 | 2012-09-28 | Ac Immune Sa | Monoclonal anti beta amyloid antibody |
| AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| WO2010053209A1 (en) * | 2008-11-05 | 2010-05-14 | Fujirebio Inc. | Method for sensing a biochemical and/or biomechanical process of a biological material and method for analyzing biological materials |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| EP2598882B1 (en) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| WO2012047732A2 (en) * | 2010-09-29 | 2012-04-12 | Genentech, Inc. | Antibody compositions and methods of use |
| CN107831318B (zh) * | 2011-01-20 | 2021-06-18 | 西瑞斯实验室有限公司 | 检测谷蛋白敏感性和其区分于乳糜泻的方法和装置 |
| BR112014029417B1 (pt) | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| JP6153019B2 (ja) | 2013-01-31 | 2017-06-28 | 国立大学法人 東京大学 | リゾホスファチジルセリン受容体機能調節活性を有する化合物 |
| EP3083697B1 (en) * | 2013-12-20 | 2019-04-17 | Development Center for Biotechnology | Alpha-enolase specific antibodies and methods of uses in cancer therapy |
| WO2015114576A1 (en) * | 2014-01-31 | 2015-08-06 | Universität Zürich | Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease |
| JP6369721B2 (ja) | 2014-07-04 | 2018-08-08 | 国立大学法人 東京大学 | リゾホスファチジルセリン誘導体 |
| GB2532426B (en) * | 2014-11-18 | 2016-11-02 | Rogers Arpi | Therapeutic homodimer and uses thereof |
| AU2014415566A1 (en) * | 2014-12-31 | 2017-07-20 | Develpment Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
| US9527922B2 (en) | 2014-12-31 | 2016-12-27 | Development Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
| KR101802302B1 (ko) | 2015-01-21 | 2017-11-28 | 가천대학교 산학협력단 | 포스파티딜이노시톨포스페이트 결합 물질의 세포 사멸 검출 용도 |
| JP6544669B1 (ja) | 2018-03-16 | 2019-07-17 | ディヴェロップメント センター フォー バイオテクノロジー | アルファエノラーゼに特異的な抗体及びその使用 |
| WO2019197610A1 (en) | 2018-04-13 | 2019-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New vaccinal strategy |
| CN110885778A (zh) * | 2018-09-07 | 2020-03-17 | 上海益诺思生物技术股份有限公司 | 从体外培养的细胞中分离Pig-a基因突变细胞的方法 |
| AU2020346886A1 (en) * | 2019-09-13 | 2022-04-14 | Memorial Hospital For Cancer And Allied Diseases | Anti-CD371 antibodies and uses thereof |
| GB202015755D0 (en) * | 2020-10-05 | 2020-11-18 | Rogers Arpi | Coronavirus therapy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| EP0388186A1 (en) | 1989-03-17 | 1990-09-19 | E.I. Du Pont De Nemours And Company | External regulation of gene expression |
| US5795965A (en) * | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| SE9102074D0 (sv) * | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5891623A (en) * | 1992-11-09 | 1999-04-06 | Consorzio Per Le Biotecnologie | Diagnosis and treatment of AIDS onset |
| GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US6001809A (en) | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
| USRE39048E1 (en) * | 1995-06-07 | 2006-03-28 | Pepscan Systems B.V. | Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine |
| US5861260A (en) | 1996-11-05 | 1999-01-19 | University Of Massachusetts | Diagnostic methods for screening patients for scleroderma |
| IL121041A0 (en) | 1997-06-09 | 1997-11-20 | Yeda Res & Dev | Immunogenic compositions for induction of anti-tumor immunity |
| EP1595951A1 (en) * | 1997-07-21 | 2005-11-16 | Arpi Matossian-Rogers | Diagnosis and treatment of diseases using peptides which are bound by specific anti-anti-t-cell receptor vbeta antibodies |
| DE19739685A1 (de) | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| US6703491B1 (en) * | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| SI1232392T1 (en) * | 1999-10-12 | 2003-10-31 | Connex Gesellschaft Zur Optimierung Von Forschung Und | Improved method for the detection of acid resistant bacteria of the genus helicobacter in stool |
| EP1130032A1 (en) * | 2000-02-28 | 2001-09-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) |
| GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| JP2001299349A (ja) * | 2000-04-19 | 2001-10-30 | Suntory Ltd | 新規組換え型抗体とそのｃｄｒのアミノ酸配列およびそれをコードする遺伝子 |
| CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| US20040115196A1 (en) * | 2001-04-18 | 2004-06-17 | Yoshiaki Fukuda | Novel recombinant antibodies, amino acid sequences of cdrs thereof and genes encoding the same |
| WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| EP1427377A4 (en) | 2001-09-20 | 2006-04-12 | Cornell Res Foundation Inc | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SKIN DISORDERS USING SPECIFIC BINDING AGENTS FOR A PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| CA2478047C (en) * | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| US8038986B2 (en) * | 2002-07-26 | 2011-10-18 | The Walter And Eliza Hall Institute Of Medical Research | Immunogenic compositions and diagnostic and therapeutic uses thereof |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| US20040136998A1 (en) * | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
| US20050009136A1 (en) * | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
| KR100500283B1 (ko) | 2003-03-25 | 2005-07-11 | 이뮤노믹스 주식회사 | 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물 |
| JP2007525458A (ja) * | 2003-04-23 | 2007-09-06 | メダレックス インコーポレイテッド | インターフェロンα受容体−１（ＩＦＮＡＲ−１）に対するヒト化抗体 |
| JP2007535905A (ja) * | 2003-06-06 | 2007-12-13 | オンコマックス アクイジション コーポレイション | 癌関連抗原ｓｍ５−１の特異抗体およびその用途 |
| EP1648511A1 (en) * | 2003-07-29 | 2006-04-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| US9403908B2 (en) | 2003-09-29 | 2016-08-02 | The Regents Of The University Of California | Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
| BRPI0922561A2 (pt) * | 2008-12-09 | 2020-08-11 | Pfizer Vaccines Llc | vacina de peptídeo de ch3 da ige. |
-
2006
- 2006-08-09 KR KR1020147008188A patent/KR101527334B1/ko not_active Expired - Fee Related
- 2006-08-09 NZ NZ566245A patent/NZ566245A/en not_active IP Right Cessation
- 2006-08-09 ES ES12198289.6T patent/ES2679994T3/es active Active
- 2006-08-09 US US11/990,281 patent/US9243062B2/en not_active Expired - Fee Related
- 2006-08-09 CN CN201510292155.1A patent/CN105017423B/zh not_active Expired - Fee Related
- 2006-08-09 NZ NZ595387A patent/NZ595387A/xx not_active IP Right Cessation
- 2006-08-09 JP JP2008525635A patent/JP2009505640A/ja active Pending
- 2006-08-09 EP EP06779101.2A patent/EP1919952B1/en active Active
- 2006-08-09 EP EP12198288.8A patent/EP2578602B1/en active Active
- 2006-08-09 GB GB0615831A patent/GB2429013C/en not_active Expired - Fee Related
- 2006-08-09 AU AU2006277785A patent/AU2006277785B2/en not_active Ceased
- 2006-08-09 NZ NZ595386A patent/NZ595386A/xx not_active IP Right Cessation
- 2006-08-09 DK DK12198289.6T patent/DK2594591T3/en active
- 2006-08-09 BR BRPI0614366-0A patent/BRPI0614366A2/pt not_active Application Discontinuation
- 2006-08-09 KR KR1020087005824A patent/KR20080039978A/ko not_active Ceased
- 2006-08-09 WO PCT/GB2006/002977 patent/WO2007017686A2/en not_active Ceased
- 2006-08-09 CA CA2618796A patent/CA2618796C/en not_active Expired - Fee Related
- 2006-08-09 EA EA200800556A patent/EA015629B1/ru not_active IP Right Cessation
- 2006-08-09 EP EP12198289.6A patent/EP2594591B1/en active Active
-
2008
- 2008-02-10 IL IL189407A patent/IL189407A/en not_active IP Right Cessation
- 2008-02-11 CU CU20080021A patent/CU23793B7/es active IP Right Grant
-
2012
- 2012-11-05 IL IL222879A patent/IL222879A/en not_active IP Right Cessation
- 2012-11-05 IL IL222880A patent/IL222880A/en active IP Right Grant
-
2013
- 2013-02-12 JP JP2013024857A patent/JP5738333B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-16 CY CY181100863T patent/CY1120640T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009505640A5 (https=) | ||
| CN101048659B (zh) | 抗前胃泌素单克隆抗体 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| US11046745B2 (en) | Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof | |
| US9221889B2 (en) | VEGF-specific capture agents, compositions, and methods of using and making | |
| CN102143978B (zh) | 抗p2x7肽和表位 | |
| JP2007536212A (ja) | レプチンアンタゴニストおよびレプチン定量測定方法 | |
| KR20160007579A (ko) | 면역요법의 임상 효과의 예측법 | |
| CN113227148A (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| JP4705694B2 (ja) | イミュノグロブリン結合能を有するペプチド | |
| JP6486914B2 (ja) | ヒト抗ｉｌ−３２抗体 | |
| Balhorn et al. | Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia | |
| CN117242092A (zh) | Vegfa结合分子 | |
| WO2021213245A1 (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| JPH02479A (ja) | ｓｎＲＮＰ−Ａ抗原及びそのフラグメント | |
| CA2401580A1 (en) | Affinity matrix bearing tumor-associated antigens | |
| CN102014955A (zh) | 含醣基广谱癌症标志物 | |
| WO2016077720A1 (en) | Binding agents and uses thereof | |
| US10570185B2 (en) | Method to detect autoantibody reactivity for deamidated insulin autoantigen in diabetes | |
| WO2010069570A2 (en) | Peptides against autoantibodies associated with crps and use of these peptides | |
| CN119505001B (zh) | 靶向cd22的全人源抗体及其应用 | |
| Itoh et al. | Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein | |
| US10975122B2 (en) | Epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection | |
| WO2025081063A2 (en) | Antibody-drug conjugate metabolites | |
| Heimburg | Characterization and exploitation of antibody to the tumor antigen TF-Ag and peptide mimics of TF-Ag to develop improved tumor immunotherapies |